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100,000 persons. RESULTS: From 2007–2009, incidence of reportable invasive SP
pneumonia decreased linearly from 11.7/100,000 to 7.1/100,000. Incidence in-
creased with age; adults aged 65 years consistently had the highest incidence
(2007: 39.4/100,000; 2009: 24.4/100,000), with the lowest rates observed in adults
aged 20–49 years (2009: 3.35/100,000). In-hospital mortality rates were 6%
throughout the study, with the highest rates in adults aged 65 years (2009: 8.8%).
SP was the most common pathogen reported (1,358/1,544 [88%] isolates). The pro-
portion of 7-valent pneumococcal conjugate vaccine (PCV7) serotypes decreased
from 46.7% to 20.1%, while the number and proportion of non-PCV7, 13-valent
pneumococcal conjugate vaccine (PCV13) serotype disease increased, led by 19A
(n7 [1.3%] to n23 [6.9%]). The most frequently identified serotypes in 2009 were
7F (16.8%), 1 (11.4%), 22F (11.4%), 4 (8.4%), 19A (6.9%), and 3 (6.6%). In children aged
0–4 years, 8, 1, and 0 cases of PCV7 invasive SP pneumonia occurred in 2007, 2008,
and 2009, respectively. PCV13 serotypes caused 64.9% of invasive SP pneumonia in
2009, the majority in adults aged60 years. CONCLUSIONS: Although incidence of
reportable invasive pneumonia decreased in Norway from 2007–2009, after the
pediatric PCV7 National Immunization Program was fully underway, substantial
disease burden remains, particularly in older adults. Almost 65% of invasive SP
pneumonia cases were caused by pneumococcal conjugate vaccine serotypes.
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OBJECTIVES: Pneumonia is associated with substantial burdens on patient mor-
bidity and mortality, and health care resources across all age groups. A retrospec-
tive database study was conducted to assess the burden of disease associated with
hospitalized all-cause pneumonia in terms of incidence, in-hospital mortality,
length-of-stay (LOS), and hospitalization cost in the Italian regions of Lombardia
and Puglia from 2007–2009. METHODS: Data were obtained from two Local Health
Units (LHUs) in Lombardia and Puglia. All patients with an ICD-9 code diagnosis of
pneumonia (480, 481, 482, 483, 484, 485, 486, and 487) from January 1, 2007–Decem-
ber 31, 2009 were included. Incidence rates were calculated based on the number of
people per LHU and reported annually as cases per 1,000 persons. RESULTS: In
total, 10,195 patients hospitalized for pneumonia were included in this study. In-
cidence of hospitalizations increased slightly from 2007–2009 (2007: 1.91/1,000;
2008: 1.86/1,000; 2009: 2.00/1,000). In children aged 0–4 years, incidence decreased
from 5.57/1,000 in 2007 to 3.85/1,000 in 2009, while incidence in adults aged 65
years increased from 5.36/1,000 to 6.59/1,000. In-hospital deaths occurred in 196
patients (5.9%) in 2007 and 202 (5.2%) patients in 2009, with the highest mortality
observed in adults aged65 years (176 patients [9.5%] and 191 [8.1%], respectively).
No in-hospital deaths occurred in children aged 0–4 years. Mean LOS was similar
(2007: 10.5 days; 2008: 10.8 days; 2009: 11.0 days), and increased with age. Mean cost
per patient was €2,966 in 2007, €3,073 in 2008, and €3,218 in 2009. CONCLUSIONS:
Reductions in hospitalized pneumonia were observed in children aged 0–4 years;
however, overall incidence of hospitalized pneumonia slightly increased during
the study period driven by increased hospitalizations in older adults. Adults aged
65 years had the highest disease burden in terms of incidence, in-hospital mor-
tality, mean hospital LOS, and costs.
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OBJECTIVES: International randomized, multicenter, double-blinded studies dem-
onstrated that boceprevir, added to peginterferon alpha-2b and ribavirin signifi-
cantly increased sustained virologic response rates over peginterferon/ribavirin
alone in treatment-naïve (SPRINT-2) and treatment-experienced (RESPOND-2)
adult patients with chronic hepatitis C virus genotype 1 infection. Our objective
was to project the reduction in the lifetime incidence of liver-related morbidity and
mortality associated with treatment with boceprevir/peginterferon/ribavirin vs.
treatment with peginterferon/ribavirin vs. no treatment. METHODS: A multi-co-
hort Markov model was developed using German life tables and baseline patient
demographics from the trials— mean age, gender, and fibrosis stage distribution.
The first part of the model simulated three strategies—treatment with boceprevir/
peginterferon/ribavirin (as defined by the European Medicines Agency), treatment
with peginterferon/ribavirin, and no treatment. The second part of the model sim-
ulated the natural history of HCV. All hepatitis C-related state transition probabil-
ities were obtained from previously published studies. Lifetime cumulative inci-
dence of decompensated cirrhosis, hepatocellular carcinoma, liver-transplant and
liver-related death was estimated. The model was validated with previously pub-
lished studies and probabilistic sensitivity analysis was performed. RESULTS: Per
10,000 treatment-experienced patients, treatment with boceprevir/peginterferon/
ribavirin vs. treatment with peginterferon/ribavirin vs. no treatment, respectively,
were associated with substantial reductions in projected cases of decompensated
cirrhosis (1082 vs. 2286 vs. 2845), hepatocellular carcinoma (719 vs. 1440 vs. 1787),
liver-transplant (154 vs. 321 vs. 398), and liver-related death (1144 vs. 2360 vs. 2920).
Likewise, substantially fewer cases of decompensated cirrhosis (1024 vs. 1835 vs.
2873), hepatocellular carcinoma (656 vs. 1161 vs. 1806), liver-transplant (146 vs. 257
vs. 402), and liver-related death (1073 vs. 1892 vs. 2954) were projected per 10,000
treatment-naïve patients. CONCLUSIONS: Boceprevir-based regimens are pro-
jected to substantially reduce the incidence of liver-related complications and
mortality in previously untreated and treatment-experienced patients chronically
infected with hepatitis C virus genotype 1 in Germany.
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OBJECTIVES: To consider reliable sources of data to assess epidemiology of hospi-
tal-acquired infections (HAI) in intensive care units (ICU).METHODS: In order to get
epidemiological data, a literature review (2002–2009) focused on bloodstream in-
fection (BSI), catheter related BSI (CR-BSI) and ventilator-associated pneumonia
(VAP) in hospital ICU in the US was performed using EMBASE database, completed
with data from Centers for Disease Control & Prevention (CDC). US hospital data-
bases (2007) were also considered to put findings in perspective: Premier Perspec-
tiveTM Hospital Database (PPHD) and State Inpatient Database (SID: part of health
care cost and utilization project (HCUP)) providing ICU data for this study.
RESULTS: The rate of ICU hospitalized patients in the US databases (9.4%) was
within the results in literature (8%-15%). The proportion of ICU patients with de-
vices was higher in literature than in SID and PPHD databases with for central line
catheters: 48%, 19%, 26.2% and for mechanical ventilation: 33%, 21.9% and 15%
respectively. CR-BSI were reported in 4.8% of ICU patients with central venous
catheter, in literature (1.4 - 5.5 /1,000 central line days), 9.4% in SID (5.7/1,000 cath-
eter/central line days) and 33.8% in PPDH*. Rate of VAP in ICU was estimated at
2.1-10.7/1,000 ventilator days in literature and 12.2/1,000 ventilator days in SID.
Proportion of VAP amongst ICU mechanically ventilated patients was similar
within the databases (12%). BSI attributable mortality was comparable in the liter-
ature (12-25%) and hospital database (24.7% in PPHD). Attributable mortality for
VAP was not found in the literature. This latter was estimated from the hospital
database (19.6% in PPHD). CONCLUSIONS: Different sources are available to esti-
mate the prevalence of HAI in ICU. Results should be interpreted with caution due
to methodology limitations (e.g. HAI case definitions). Nevertheless, real-life data-
bases appear appropriate to estimate attributable mortality of HAI in ICU. * central
venous/line catheter.
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OBJECTIVES: To evaluate treatment outcomes in tuberculosis patients with and
without diabetes mellitus. METHODS: This was a retrospective cohort study con-
ducted at respiratory clinic of Hospital Pulau Pinang (HPP), Malaysia. All Tubercu-
losis (TB) patients who were presented to the clinic from January 2006 to December
2007 were included in the study. A purpose developed valid data collection form
was used for collecting demographic and clinical data. Treatment outcomes ini-
tially recorded as cured, treatment completed, defaulted, transferred out, expired
and treatment continued were then classified into two categories; successful and
unsuccessful treatment. Cured and treatment completed patients were placed in
treatment successful category while the rest were placed in the category of unsuc-
cessful treatment. Data was analyzed by using SPSS 16®. RESULTS: Final analysis
included 1266 patients.Three hundred and thirty eight patients (26.7%) had DM
along with TB. In multivariate analysis TB-DM was more likely to be present in
Chinese (OR 1.470, p-value 0.003), married patients (OR 1.408, p-value 0.011)
and patients having age 46-60 years (OR 2.002, p-value0.001), and 60 years (OR
 1.594, p-value  0.010). Nine hundred and eighty five (78.8%) patients were suc-
cessfully treated. Successful Treatment was observed in patients having age of
46-60 years (OR 1.567, p-value 0.001), whereas male gender (OR 0.721, p-value
 0.049) and patients with relapse TB (OR  0.494, p-value  0.002) were less likely
to have successful treatment. CONCLUSIONS: In the present study Chinese ethnic-
ity, age ( 46 years) and being married were the predictors of prevalence of TB-DM.
Majority patients were successfully treated. Male gender and patients with relapse
TB were the predictors of treatment failure. No statistically significant difference in
treatment outcomes was observed between TB patients with and without diabetes
mellitus.
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OBJECTIVES:Despite the availability of highly efficacious pharmacotherapy, tuber-
culosis (TB) still remains as a major public health problem globally. The aim of the
present study was to evaluate TB treatment outcomes in four high burden TB states
of Malaysia. METHODS: This was a retrospective prospective study conducted at
TB clinics of Penang, Sabah, Sarawak and Selangor. All TB patients who were pre-
sented to the clinics from January 2006 to December 2008 were included in the
study. A purpose developed valid data collection form was used for collecting de-
mographic and clinical data. World Health Organization (WHO) defined criteria
was used for defining treatment outcomes. Data was analyzed by using SPSS 16®.
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